Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Competing interests: P.J.G. has received honoraria for grant review and a symposium from the Pharma Mar Foundation; served as advisor for OrphAI therapeutics with options and honoraria for advisory board participation for Jazz and Inhibrx; and received support to his institution from Janssen Scientific Affairs, LLC. L.M. has received honoraria for work products from Novartis; received consultant, travel and accommodation compensation for scientific presentations from Bayer; and has uncompensated relationships with the Children’s Oncology Group (COG) Foundation, the COG Research Foundation, the COG Bone Tumor Committee and the Pablove Foundation. S.G.D. has provided consulting for Bayer, Amgen, Jazz Pharmaceuticals, InhibRx, EMD Serono and Merck. R.G.M. has received consulting fees or honoraria from Boehringer Ingelheim, Deciphera, Ipsen, Physicians’ Education Resource, the American Board of Internal Medicine, the American Society for Clinical Oncology and Peel Therapeutics and receives royalties from UpToDate for sarcoma-related content and stock from Peel Therapeutics for work with Peel. T.W.L. participates in consulting/advisory boards for Advanced Microbubbles, OrphAI Therapeutics, Bayer, GlaxoSmithKline, ITM Oncologics and Jazz Pharmaceuticals and receives research support to his institution from Bayer, Pfizer, Eli Lilly and Exelixis. D.K.R. has received honoraria for advisory boards from Boehringer Ingelheim and Merck. R.C. has done advisory work for Deciphera, Recordati and Cogent Biosciences and receives royalties from UpToDate with all research support going to her institution. R.H., M.F.W., K.B., E.A.B., J.M.G., E.R.W., E.T., B.S., L.F.S., C.R., K.K., F.N., G.L., S.T., R.K., R.D.R., M.H., E.M., L.O., C.P., K.S., M.S.D., W.D.F., R.B., M.L.L., P.L.C., B.D.C., B.C.W. and J.G.G. declare no competing interests.